Istituto Oncologico Veneto Research Articles

Evaluations Of New Drugs After They Reach The Market

Letters Health AffairsVol. 30, No. 10: Agenda For Fighting Disparities Evaluations Of New Drugs After They Reach The MarketAntonio Jirillo and Marta P. Trojniak Affiliations Istituto Oncologico Veneto I.R.C.C.S. Padua, Italy PUBLISHED:October 2011No Accesshttps://doi.org/10.1377/hlthaff.2011.0967AboutSectionsView articleView Full TextView PDFPermissions ShareShare onFacebookTwitterLinked InRedditEmail ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions View article"Evaluations Of New Drugs After They Reach The Market." Health Affairs, 30(10), p. 2028TOPICSPharmaceuticalsAccess to care Loading Comments... Please enable JavaScript to view the comments powered by Disqus. DetailsExhibitsReferencesRelated Article Metrics History Published online 1 October 2011 Information Project HOPE—The People-to-People Health Foundation, Inc. PDF download

Tolerability of PLD/Oxaliplatin Regimen in Recurrent Ovarian Cancer Patients With Previous Fragility to Carboplatin/Paclitaxel Treatment

This retrospective analysis aims at describing the safety profile of treatment with pegylated liposomal doxorubicin (PLD) and oxaliplatin in recurrent ovarian cancer patients who experienced myelotoxicity (principally neutropenia) during first line chemotherapy with carboplatin and paclitaxel. We reviewed the medical records of patients with relapsed ovarian cancer treated with PLD/Oxaliplatin at the Istituto Oncologico Veneto (IOV)/IRCCS, Padua University between 2002 and 2008. A cohort of 16 patients who developed myelodepression and other toxicities of grade 3 to grade 4 during first line chemotherapy with carboplatin/paclitaxel, were selected for this retrospective study. Patients had developed predominantly grade 3 to grade 4 neutropenia and grade 1 to grade 3 thrombocytopenia as major toxicities during primary chemotherapy with carboplatin and paclitaxel. Following relapse or disease progression, PLD/oxaliplatin chemotherapy was administered at 30 to 35 and 70 mg/m(2), respectively, over 2 day, every 4 weeks. Complete regression and stabilization of bone marrow suppression and no allergic reactions were seen with PLD/oxaliplatin treatment. The estimated median overall survival was 51.2 months. PLD/oxaliplatin chemotherapy did not show hematological toxicity and was feasible and active in this group of pretreated frail patients.

Can bone biopsies be used to confirm metastatic disease recurrence and receptor status in breast cancer patients?

Bone mineral density and bone remodelling markers osteocalcin and alkaline phosphatase in patients with Stage IV breast cancer F. Lumachi*, V. Camozzi, G. Luisetto, R. Orlando, S.M.M. Basso, A. Brunello, U. Basso Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, 35128 Padova, Italy Department of Medical and Surgical Sciences, University of Padua, School of Medicine, 35128 Padova, Italy UO Chirurgia 1, S Maria degli Angeli Hospital, 33170 Pordenone, Italy Istituto Oncologico Veneto (IOV) IRCCS, 35128 Padova, Italy

547 CHOLANGIOCARCINOMA IN ITALY: A NATIONAL SURVEY ON DEMOGRAPHIC AND CLINICAL CHARACTERISTICS, DIAGNOSTIC MODALITIES AND TREATMENT

547 CHOLANGIOCARCINOMA IN ITALY: A NATIONAL SURVEY ON DEMOGRAPHIC AND CLINICAL CHARACTERISTICS, DIAGNOSTIC MODALITIES AND TREATMENT

Clinical tip: use of a manual dermatoscope with a compact digital camera in a pigmented lesion clinic

Skin Research and TechnologyVolume 15, Issue 4 p. 511-513 Clinical tip: use of a manual dermatoscope with a compact digital camera in a pigmented lesion clinic Edoardo Zattra, Edoardo Zattra Dermatology Unit, University of Padua, Padova, Italy,Search for more papers by this authorElena Tonin, Elena Tonin Melanoma Unit, Istituto Oncologico Veneto (IOV), Padua, Italy, andSearch for more papers by this authorAnna Belloni Fortina, Anna Belloni Fortina Dermatology Unit, Department of Pediatrics, University of Padua, Padova, ItalySearch for more papers by this authorBarbara Pigozzi, Barbara Pigozzi Melanoma Unit, Istituto Oncologico Veneto (IOV), Padua, Italy, andSearch for more papers by this authorMauro Alaibac, Mauro Alaibac Dermatology Unit, University of Padua, Padova, Italy,Search for more papers by this author Edoardo Zattra, Edoardo Zattra Dermatology Unit, University of Padua, Padova, Italy,Search for more papers by this authorElena Tonin, Elena Tonin Melanoma Unit, Istituto Oncologico Veneto (IOV), Padua, Italy, andSearch for more papers by this authorAnna Belloni Fortina, Anna Belloni Fortina Dermatology Unit, Department of Pediatrics, University of Padua, Padova, ItalySearch for more papers by this authorBarbara Pigozzi, Barbara Pigozzi Melanoma Unit, Istituto Oncologico Veneto (IOV), Padua, Italy, andSearch for more papers by this authorMauro Alaibac, Mauro Alaibac Dermatology Unit, University of Padua, Padova, Italy,Search for more papers by this author First published: 11 October 2009 https://doi.org/10.1111/j.1600-0846.2009.00388.x Address:Prof. Mauro AlaibacDermatology UnitUniversity of PaduaVia C. Battisti 206Padova 35128ItalyTel: +39 49 821 2901Fax: +39 49 821 2502e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Volume15, Issue4November 2009Pages 511-513 RelatedInformation

Paraneoplastic diffuse cutaneous papillomatosis

Journal of the European Academy of Dermatology and VenereologyVolume 23, Issue 2 p. 220-221 Paraneoplastic diffuse cutaneous papillomatosis F Zustovich, Corresponding Author F Zustovich *Correspondence: F Zustovich. E-mail: [email protected]Search for more papers by this authorG Lombardi, G Lombardi Oncologia Medica 1, Istituto Oncologico Veneto – IRCCS, Padova, ItalySearch for more papers by this authorG Cartei, G Cartei Oncologia Medica 1, Istituto Oncologico Veneto – IRCCS, Padova, ItalySearch for more papers by this author F Zustovich, Corresponding Author F Zustovich *Correspondence: F Zustovich. E-mail: [email protected]Search for more papers by this authorG Lombardi, G Lombardi Oncologia Medica 1, Istituto Oncologico Veneto – IRCCS, Padova, ItalySearch for more papers by this authorG Cartei, G Cartei Oncologia Medica 1, Istituto Oncologico Veneto – IRCCS, Padova, ItalySearch for more papers by this author First published: 20 January 2009 https://doi.org/10.1111/j.1468-3083.2008.02812.xCitations: 2 DOI: 10.1111/j.1468-3083.2008.02812.x Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume23, Issue2February 2009Pages 220-221 RelatedInformation

Reply: The easiest way to improve the outcome of suboptimal liver grafts

Transaminase levels on the seventh postoperative day in the single aortic perfusion (SAP) group were only minimally influenced by the high incidence of early graft losses in this group. In fact, 3 patients having primary dysfunction (PDF) died within the first post-LT week, whereas 2 other patients were successfully retransplanted for PDF. Thus, patients in the SAP group, who were alive on the seventh postoperative day, had transaminase levels similar to those of patients in the modified double perfusion (MDP) group. The study by de Ville de Goyet et al.3 was a retrospective analysis of an old series. In that study, the authors compared the SAP technique with the classical aortic and portal cooling technique without our expedient of a tourniquet surrounding the portal vein to be tightened immediately after cross-clamping (MDP technique). The authors found significant differences not in the overall immediate graft function but only in the postoperative peak of glutamic pyruvic transaminase. Moreover, they considered only optimal donors and used only a University of Wisconsin (UW) solution as a preservative fluid. Thus, several methodological and technical differences make de Ville de Goyet et al.'s conclusions not comparable with those of our study. Further prospective studies with a larger study population are necessary to explain the role of the preservation solution in suboptimal livers. However, we have recently performed a multicenter, prospective, randomized pilot study4 comparing Celsior and UW solutions in the context of LT. That study also evaluated a significant proportion of suboptimal donors (around 20%). In the subgroup of patients receiving a suboptimal liver (data not shown), the prevalence of PDF was higher in the UW group, but this difference did not reach statistical significance. Cold ischemia time (CIT) and histologically determined liver steatosis were used as major criteria to define suboptimal livers in our study, although they obviously cannot be known at the time of organ procurement. This choice of study design was aimed to avoid the potential bias deriving from excluding factors capable of significantly influencing graft performance in the analysis. This methodological aspect may explain the high mean values of CIT in the 2 groups. As suggested by Jeon and Ranjan and already remarked in our discussion, however, it is possible that the preventive adoption of a lower CIT could have lowered the difference in PDF prevalence between the SAP and MDP groups. We have no experience with organ procurement from donors after cardiac death. In such donors, the SAP technique is probably a more suitable procurement tool. The adoption of a lower CIT is advisable, especially in those cases in which a potential “at risk” donor is allocated. We are performing a randomized controlled trial (begun on December 2006) evaluating the role of a systemic (at the beginning of the harvesting procedure) and loco-regional infusion (intraportal vein infusion just before cross-clamping) of N-acetyl cysteine during liver procurement. In this study, we have maintained low CIT values, and we have defined suboptimal livers only on the basis of preoperative characteristics (major criteria: ultrasound steatosis and/or body mass index > 30, partial graft, age > 60 years, and hepatitis C virus or hepatitis B surface antigen positivity). The preliminary results of this study (after the first 12 months of enrolment) have shown a statistically significantly lower incidence of PDF in patients in the N-acetyl cysteine group. The use of graft machine perfusion preserving methods during the procurement procedure may improve the post-LT outcome of suboptimal livers. In this context, we are developing a subnormothermic machine perfusion model in pigs for the preservation of suboptimal grafts. An optimal donor-recipient match5 represents a crucial issue to overcome the risk of post-LT PDF. In conclusion, as suggested by Jeon and Ranjan, the MDP technique is only one of the possible tools to optimize the results of LT with suboptimal livers. The reduction of CIT median values, the use of non–heart-beating donors, the infusion of antioxidant agents, the introduction of a graft machine perfusion model, and the application of an optimal donor-recipient match are all potential instruments of a multimodal strategy aimed at improving the outcome of suboptimal livers and at extending and standardizing the use of such a relevant resource for LT candidates. Francesco D'Amico*, Alessandro Vitale , Alberto Brolese*, Giacomo Zanus*, Umberto Cillo*, * Unità di Chirurgia Epatobiliare e Trapianto Epatico Dipartimento Assistenziale di Chirurgia Generale e Trapianti d'Organo Azienda Ospedaliera di Padova Padova, Italy, Unità di Chirurgia Oncologica Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico Padova, Italy.